Loading...

Czernin, Johannes

Title(s)Professor, Molecular And Medical Pharmacology
Phone3102063226
vCardDownload vCard
    Other Positions
    Title(s)Professor, Medicine


    Collapse Research 
    Collapse Research Activities and Funding
    PET Imaging-guided Personalized Therapy in Pancreatic Cancer
    NIH/NCI R01CA187678Aug 18, 2014 - Jul 31, 2019
    Role: Co-Principal Investigator
    A New Theranostic System for PET Image Guided Radiotherapy of Cancer
    NIH/NCI R21CA179322Jul 1, 2013 - Jun 30, 2015
    Role: Principal Investigator
    Novel molecular imaging approaches to monitor gene and cell-based therapies
    NIH/NCI R01CA160770Sep 1, 2011 - Aug 31, 2014
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Oughourlian TC, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. J Neurooncol. 2020 Jan 24. PMID: 31981013.
      View in: PubMed
    2. Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Investigating PSMA-targeted radioligand therapy efficacy as a function of cellular PSMA levels and intra-tumoral PSMA heterogeneity. Clin Cancer Res. 2020 Jan 13. PMID: 31932492.
      View in: PubMed
    3. Sonni I, Eiber M, Fendler WP, Alano RM, Vangala SS, Kishan AU, Nickols N, Rettig MB, Reiter R, Czernin J, Calais J. Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single Center Study. J Nucl Med. 2020 Jan 10. PMID: 31924715.
      View in: PubMed
    4. Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, Czernin J, Haberkorn U, Calais J. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2019 Dec 13. PMID: 31836685.
      View in: PubMed
    5. Gafita A, Calais J, Franz C, Rauscher I, Wang H, Roberstson A, Czernin J, Weber WA, Eiber M. Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis. EJNMMI Res. 2019 Dec 02; 9(1):103. PMID: 31792771.
      View in: PubMed
    6. Czernin J, Allen-Auerbach M, Calais J. Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost Arguments. J Nucl Med. 2019 Dec; 60(12):1657-1658. PMID: 31792126.
      View in: PubMed
    7. Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, Damoiseaux R, Czernin J, Donahue TR, Lavie A, Radu CG. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chem Biol. 2020 Feb 20; 27(2):197-205.e6. PMID: 31734178.
      View in: PubMed
    8. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Fendler WP, Czernin J. What is the best PET target for early biochemical recurrence of prostate cancer?-Authors' reply. Lancet Oncol. 2019 Nov; 20(11):e609-e610. PMID: 31674314.
      View in: PubMed
    9. Haberkorn U, Czernin J. A Conversation Between Uwe Haberkorn and Johannes Czernin. J Nucl Med. 2019 Nov; 60(11):1495-1498. PMID: 31676705.
      View in: PubMed
    10. de Vries E, Czernin J. A Conversation Between Elisabeth de Vries and Johannes Czernin. J Nucl Med. 2019 10; 60(10):1337-1339. PMID: 31575716.
      View in: PubMed
    11. Pomykala KL, Czernin J, Grogan TR, Armstrong WR, Williams J, Calais J. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. J Nucl Med. 2020 Mar; 61(3):405-411. PMID: 31541035.
      View in: PubMed
    12. Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 Dec 15; 25(24):7448-7454. PMID: 31511295.
      View in: PubMed
    13. Czernin J, Sonni I, Razmaria A, Calais J. The Future of Nuclear Medicine as an Independent Specialty. J Nucl Med. 2019 Sep; 60(Suppl 2):3S-12S. PMID: 31481589.
      View in: PubMed
    14. Fowler JS, Czernin J. A Conversation Between Joanna Fowler and Johannes Czernin. J Nucl Med. 2019 Sep; 60(9):1191-1193. PMID: 31481591.
      View in: PubMed
    15. Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019 Nov; 46(12):2536-2544. PMID: 31440799.
      View in: PubMed
    16. Czernin J. Toward Independent Nuclear Medicine, Molecular Imaging, and Theranostic Programs. J Nucl Med. 2019 Aug; 60(8):1037. PMID: 31371618.
      View in: PubMed
    17. Hricak H, Czernin J. A Conversation Between Hedvig Hricak and Johannes Czernin. J Nucl Med. 2019 Aug; 60(8):1038-1041. PMID: 31371619.
      View in: PubMed
    18. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 Sep; 20(9):1286-1294. PMID: 31375469.
      View in: PubMed
    19. Rauscher I, Fendler WP, Hope TA, Quon A, Nekolla SG, Calais J, Richter A, Haller B, Herrmann K, Weber WA, Czernin J, Eiber M. Can the Injected Dose Be Reduced in 68Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection? J Nucl Med. 2020 Feb; 61(2):189-193. PMID: 31324710.
      View in: PubMed
    20. Zhu S, Mosessian S, Kroeger K, Sadeghi S, Slavik R, Kinloch S, Moore M, Allen-Auerbach M, Czernin J, Phelps M. Transforming an Academic Radiochemistry Facility for Positron Emission Tomography Drug cGMP Compliance. Mol Imaging Biol. 2019 Jun 25. PMID: 31240531.
      View in: PubMed
    21. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):856-863. PMID: 30920593.
      View in: PubMed
    22. Volkow N, Czernin J. A Conversation Between Nora Volkow and Johannes Czernin. J Nucl Med. 2019 Jun; 60(6):717-720. PMID: 31160430.
      View in: PubMed
    23. Schwaiger M, Czernin J. A Conversation Between Markus Schwaiger and Johannes Czernin. J Nucl Med. 2019 05; 60(5):573-576. PMID: 31043502.
      View in: PubMed
    24. Cherry SR, Czernin J. Discussions with Leaders: A Conversation between Simon Cherry and Johannes Czernin. J Nucl Med. 2019 03; 60(3):295-298. PMID: 30824670.
      View in: PubMed
    25. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Correction to: Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 01 21; 19(1):97. PMID: 30665383.
      View in: PubMed
    26. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019 Jan 07; 19(1):18. PMID: 30616601.
      View in: PubMed
    27. Razmaria A, Calais J, Czernin J. Delivering Radionuclide Therapies Requires Extensive Training and Competence: Send a Firm Message to the NRC and Your Representatives. J Nucl Med. 2019 01; 60(1):1-2. PMID: 30602593.
      View in: PubMed
    28. Wahl RL, Czernin J. Discussions with Leaders: A Conversation Between Richard Wahl and Johannes Czernin. J Nucl Med. 2019 01; 60(1):3-6. PMID: 30602594.
      View in: PubMed
    29. Czernin J, Gambhir SS. Discussions with Leaders: A Conversation Between Sam Gambhir and Johannes Czernin. J Nucl Med. 2018 12; 59(12):1783-1785. PMID: 30510073.
      View in: PubMed
    30. Maddahi J, Bengel F, Czernin J, Crane P, Dahlbom M, Schelbert H, Sparks R, Phelps M, Lazewatsky J. Dosimetry, biodistribution, and safety of flurpiridaz F 18 in healthy subjects undergoing rest and exercise or pharmacological stress PET myocardial perfusion imaging. J Nucl Cardiol. 2019 Dec; 26(6):2018-2030. PMID: 30488323.
      View in: PubMed
    31. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018 Oct 29; 8(1):96. PMID: 30374743.
      View in: PubMed
    32. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2019 02; 17(1):e53-e55. PMID: 30293922.
      View in: PubMed
    33. Czernin J. The Quality and Impact of JNM. J Nucl Med. 2018 09; 59(9):1337. PMID: 30181230.
      View in: PubMed
    34. Czernin J. Is This Whom We Have Become? J Nucl Med. 2018 Aug; 59(8):1171. PMID: 30072475.
      View in: PubMed
    35. Czernin J, Ceci F. Aetna and 68Ga-DOTATATE: A Sequel to "The Injustice of Being Judged by the Errors of Others". J Nucl Med. 2018 05; 59(5):721-722. PMID: 29717082.
      View in: PubMed
    36. Patel CB, Fazzari E, Chakhoyan A, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. J Neurooncol. 2018 Sep; 139(2):399-409. PMID: 29679199.
      View in: PubMed
    37. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 11; 59(11):1714-1721. PMID: 29653978.
      View in: PubMed
    38. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med. 2018 09; 59(9):1392-1397. PMID: 29602819.
      View in: PubMed
    39. Czernin J. The National Oncologic PET Registry (NOPR): A Monumental Effort by a Few Leaders. J Nucl Med. 2018 03; 59(3):379. PMID: 29497001.
      View in: PubMed
    40. Czernin J. The National Oncology PET Registry (NOPR): A monumental effort by a few leaders. J Nucl Med. 2018 Jan 25. PMID: 29371409.
      View in: PubMed
    41. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. PMID: 29242398.
      View in: PubMed
    42. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. J Nucl Med. 2018 02; 59(2):230-237. PMID: 29123013.
      View in: PubMed
    43. Czernin J. Is 16 Months of Specialized Nuclear Medicine Training Enough for Best Patient Care? J Nucl Med. 2017 10; 58(10):1535. PMID: 28970350.
      View in: PubMed
    44. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10220-10225. PMID: 28874539.
      View in: PubMed
    45. Boas Z, Gupta P, Moheimani RS, Bhetraratana M, Yin F, Peters KM, Gornbein J, Araujo JA, Czernin J, Middlekauff HR. Activation of the "Splenocardiac Axis" by electronic and tobacco cigarettes in otherwise healthy young adults. Physiol Rep. 2017 Sep; 5(17). PMID: 28899908.
      View in: PubMed
    46. Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblum HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, Donahue TR, Czernin J, Radu CG. ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. Nat Commun. 2017 08 14; 8(1):241. PMID: 28808226.
      View in: PubMed
    47. Czernin J. The Impact of the Impact Factor. J Nucl Med. 2017 08; 58(8):1185. PMID: 28765226.
      View in: PubMed
    48. Fendler WP, Stuparu AD, Evans-Axelsson S, Lückerath K, Wei L, Kim W, Poddar S, Said J, Radu CG, Eiber M, Czernin J, Slavik R, Herrmann K. Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. J Nucl Med. 2017 11; 58(11):1786-1792. PMID: 28546332.
      View in: PubMed
    49. Czernin J, Eiber M. Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail? J Nucl Med. 2017 08; 58(8):1186-1187. PMID: 28473599.
      View in: PubMed
    50. Calais J, Czernin J, Eiber M, Fendler WP, Gartmann J, Heaney AP, Hendifar AE, Pisegna JR, Hecht JR, Wolin EM, Slavik R, Gupta P, Quon A, Schiepers C, Allen-Auerbach MS, Herrmann K. Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented. J Nucl Med. 2017 11; 58(11):1793-1796. PMID: 28473600.
      View in: PubMed
    51. Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, Gupta P, Hartenbach M, Hope TA, Okamoto S, Pfob CH, Pöppel TD, Rischpler C, Schwarzenböck S, Stebner V, Unterrainer M, Zacho HD, Maurer T, Gratzke C, Crispin A, Czernin J, Herrmann K, Eiber M. 68Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. J Nucl Med. 2017 10; 58(10):1617-1623. PMID: 28408531.
      View in: PubMed
    52. Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017 01 18; 9(373). PMID: 28100832.
      View in: PubMed
    53. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Rep. 2017 01 17; 18(3):601-610. PMID: 28099841.
      View in: PubMed
    54. Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, Eiber M, Herrmann K, Fendler WP. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. J Nucl Med. 2017 May; 58(5):756-761. PMID: 28082438.
      View in: PubMed
    55. Czernin J. Molecular Imaging and Therapy with a Purpose: A Renaissance of Nuclear Medicine. J Nucl Med. 2017 01; 58(1):21A-22A. PMID: 28062715.
      View in: PubMed
    56. Barrio M, Czernin J, Yeh MW, Palma Diaz MF, Gupta P, Allen-Auerbach M, Schiepers C, Herrmann K. The incidence of thyroid cancer in focal hypermetabolic thyroid lesions: an 18F-FDG PET/CT study in more than 6000 patients. Nucl Med Commun. 2016 Dec; 37(12):1290-1296. PMID: 27612034.
      View in: PubMed
    57. Barrio MJ, Spick C, Radu CG, Lassmann M, Eberlein U, Allen-Auerbach M, Schiepers C, Slavik R, Czernin J, Herrmann K. Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. J Nucl Med. 2017 03; 58(3):374-378. PMID: 27811125.
      View in: PubMed
    58. Barrio M, Fendler WP, Czernin J, Herrmann K. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Rev Mol Diagn. 2016 11; 16(11):1177-1188. PMID: 27679869.
      View in: PubMed
    59. Spick C, Herrmann K, Czernin J. Evaluation of Prostate Cancer with 11C-Acetate PET/CT. J Nucl Med. 2016 Oct; 57(Suppl 3):30S-37S. PMID: 27694168.
      View in: PubMed
    60. Fendler WP, Barrio M, Spick C, Allen-Auerbach M, Ambrosini V, Benz M, Bluemel C, Grewal RK, Lapa C, Miederer M, Nicolas G, Schuster T, Czernin J, Herrmann K. 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. J Nucl Med. 2017 02; 58(2):307-311. PMID: 27539839.
      View in: PubMed
    61. Fendler WP, Czernin J, Herrmann K, Beyer T. Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. J Nucl Med. 2016 Dec; 57(12):2016-2021. PMID: 27516448.
      View in: PubMed
    62. Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin Nucl Med. 2016 Jul; 41(7):515-21. PMID: 26975008.
      View in: PubMed
    63. Boschi S, Lee JT, Beykan S, Slavik R, Wei L, Spick C, Eberlein U, Buck AK, Lodi F, Cicoria G, Czernin J, Lassmann M, Fanti S, Herrmann K. Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. Eur J Nucl Med Mol Imaging. 2016 Nov; 43(12):2122-2130. PMID: 27329046.
      View in: PubMed
    64. Kim W, Le TM, Wei L, Poddar S, Bazzy J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubi SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, Donahue TR, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proc Natl Acad Sci U S A. 2016 Apr 12; 113(15):4027-32. PMID: 27035974.
      View in: PubMed
    65. Czernin J, Mankoff D. Introduction and Overview. J Nucl Med. 2016 Feb; 57 Suppl 1:1S-2S. PMID: 26834097.
      View in: PubMed
    66. Spick C, Herrmann K, Czernin J. 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. J Nucl Med. 2016 Mar; 57(3):420-30. PMID: 26742709.
      View in: PubMed
    67. Czernin J. Reply: Roundtable on the Future of Nuclear Medicine Training. J Nucl Med. 2015 Dec; 56(12):1969-70. PMID: 26429954.
      View in: PubMed
    68. Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Mol Imaging Biol. 2015 Jun; 17(3):434-42. PMID: 25465392.
      View in: PubMed
    69. Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015 Jun; 56(6):855-61. PMID: 25883128.
      View in: PubMed
    70. Herrmann K, Czernin J, Wolin EM, Gupta P, Barrio M, Gutierrez A, Schiepers C, Mosessian S, Phelps ME, Allen-Auerbach MS. Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective. J Nucl Med. 2015 Jan; 56(1):70-5. PMID: 25500825.
      View in: PubMed
    71. Karantanis D, Kalkanis D, Czernin J, Herrmann K, Pomykala KL, Bogsrud TV, Subramaniam RM, Lowe VJ, Allen-Auerbach MS. Perceived misinterpretation rates in oncologic 18F-FDG PET/CT studies: a survey of referring physicians. J Nucl Med. 2014 Dec; 55(12):1925-9. PMID: 25453041.
      View in: PubMed
    72. Lapa C, Linsenmann T, Monoranu CM, Samnick S, Buck AK, Bluemel C, Czernin J, Kessler AF, Homola GA, Ernestus RI, Löhr M, Herrmann K. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients. J Nucl Med. 2014 Oct; 55(10):1611-6. PMID: 25125481.
      View in: PubMed
    73. Mosessian S, Duarte-Vogel SM, Stout DB, Roos KP, Lawson GW, Jordan MC, Ogden A, Matter C, Sadeghi S, Mills GQ, Schelbert HR, Radu CG, Czernin J, Couto M, Phelps ME. INDs for PET molecular imaging probes-approach by an academic institution. Mol Imaging Biol. 2014 Aug; 16(4):441-8. PMID: 24733693.
      View in: PubMed
    74. Packard RR, Huang SC, Dahlbom M, Czernin J, Maddahi J. Absolute quantitation of myocardial blood flow in human subjects with or without myocardial ischemia using dynamic flurpiridaz F 18 PET. J Nucl Med. 2014 Sep; 55(9):1438-44. PMID: 25071096.
      View in: PubMed
    75. Wieder HA, Lassmann M, Allen-Auerbach MS, Czernin J, Herrmann K. Clinical use of bone-targeting radiopharmaceuticals with focus on alpha-emitters. World J Radiol. 2014 Jul 28; 6(7):480-5. PMID: 25071888.
      View in: PubMed
    76. Bailey DL, Barthel H, Beuthin-Baumann B, Beyer T, Bisdas S, Boellaard R, Czernin J, Drzezga A, Ernemann U, Franzius C, Gückel B, Handgretinger R, Hartenbach M, Hellwig D, Nadel H, Nekolla SG, Pfluger T, Pichler BJ, Quick HH, Sabri O, Sattler B, Schäfer J, Schick F, Siegel BA, Schlemmer HP, Schwenzer NF, van den Hoff J, Veit-Haibach P, Wehrl HF. Combined PET/MR: Where are we now? Summary report of the second international workshop on PET/MR imaging April 8-12, 2013, Tubingen, Germany. Mol Imaging Biol. 2014 Jun; 16(3):295-310. PMID: 24668195.
      View in: PubMed
    77. Czernin J, Ta L, Herrmann K. Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. J Nucl Med. 2014 Jun 01; 55(Supplement 2):59S-62S. PMID: 24812246.
      View in: PubMed
    78. Czernin J, Schwaiger M, Townsend D. Introduction. J Nucl Med. 2014 Jun 01; 55(Supplement 2):1S. PMID: 24799617.
      View in: PubMed
    79. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014 Jul 01; 20(13):3550-9. PMID: 24687922.
      View in: PubMed
    80. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. PMID: 24634374.
      View in: PubMed
    81. Nathanson DA, Armijo AL, Tom M, Li Z, Dimitrova E, Austin WR, Nomme J, Campbell DO, Ta L, Le TM, Lee JT, Darvish R, Gordin A, Wei L, Liao HI, Wilks M, Martin C, Sadeghi S, Murphy JM, Boulos N, Phelps ME, Faull KF, Herschman HR, Jung ME, Czernin J, Lavie A, Radu CG. Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication. J Exp Med. 2014 Mar 10; 211(3):473-86. PMID: 24567448.
      View in: PubMed
    82. Lapa C, Linz C, Bluemel C, Mottok A, Mueller-Richter U, Kuebler A, Schneider P, Czernin J, Buck AK, Herrmann K. Three-phase bone scintigraphy for imaging osteoradionecrosis of the jaw. Clin Nucl Med. 2014 Jan; 39(1):21-5. PMID: 24300350.
      View in: PubMed
    83. Javed MR, Chen S, Kim HK, Wei L, Czernin J, Kim CJ, van Dam RM, Keng PY. Efficient radiosynthesis of 3'-deoxy-3'-18F-fluorothymidine using electrowetting-on-dielectric digital microfluidic chip. J Nucl Med. 2014 Feb; 55(2):321-8. PMID: 24365651.
      View in: PubMed
    84. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol. 2014 Apr; 16(4):603-9. PMID: 24305722.
      View in: PubMed
    85. Lizarraga KJ, Allen-Auerbach M, Czernin J, DeSalles AA, Yong WH, Phelps ME, Chen W. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. J Nucl Med. 2014 Jan; 55(1):30-6. PMID: 24167081.
      View in: PubMed
    86. Murphy JM, Armijo AL, Nomme J, Lee CH, Smith QA, Li Z, Campbell DO, Liao HI, Nathanson DA, Austin WR, Lee JT, Darvish R, Wei L, Wang J, Su Y, Damoiseaux R, Sadeghi S, Phelps ME, Herschman HR, Czernin J, Alexandrova AN, Jung ME, Lavie A, Radu CG. Development of new deoxycytidine kinase inhibitors and noninvasive in vivo evaluation using positron emission tomography. J Med Chem. 2013 Sep 12; 56(17):6696-708. PMID: 23947754.
      View in: PubMed
    87. Czernin J, Herrmann K. The potential of PET/MRI imaging in oncology: a comment to a summary report of the First PET/MRI Workshop in Tuebingen in 2012. Mol Imaging Biol. 2013 Aug; 15(4):372-3. PMID: 23689984.
      View in: PubMed
    88. Allen-Auerbach M, de Vos S, Czernin J. PET/computed tomography and lymphoma. Radiol Clin North Am. 2013 Sep; 51(5):833-44. PMID: 24010908.
      View in: PubMed
    89. Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PET/CT in Oncology: Current Status and Perspectives. Curr Radiol Rep. 2013; 1:177-190. PMID: 24883234.
      View in: PubMed
    90. Herrmann K, Dahlbom M, Nathanson D, Wei L, Radu C, Chatziioannou A, Czernin J. Evaluation of the Genisys4, a bench-top preclinical PET scanner. J Nucl Med. 2013 Jul; 54(7):1162-7. PMID: 23628700.
      View in: PubMed
    91. Amaraesekera B, Marchis PD, Bobinski KP, Radu CG, Czernin J, Barrio JR, Michael van Dam R. High-pressure, compact, modular radiosynthesizer for production of positron emitting biomarkers. Appl Radiat Isot. 2013 Aug; 78:88-101. PMID: 23702794.
      View in: PubMed
    92. Berman DS, Maddahi J, Tamarappoo BK, Czernin J, Taillefer R, Udelson JE, Gibson CM, Devine M, Lazewatsky J, Bhat G, Washburn D. Phase II safety and clinical comparison with single-photon emission computed tomography myocardial perfusion imaging for detection of coronary artery disease: flurpiridaz F 18 positron emission tomography. J Am Coll Cardiol. 2013 Jan 29; 61(4):469-477. PMID: 23265345.
      View in: PubMed
    93. Mocharla VP, Walsh JC, Padgett HC, Su H, Fueger B, Weber WA, Czernin J, Kolb HC. From in situ to in vivo: an in situ click-chemistry-derived carbonic anhydrase II imaging agent for positron emission tomography. ChemMedChem. 2013 Jan; 8(1):43-8. PMID: 23208787.
      View in: PubMed
    94. Austin WR, Armijo AL, Campbell DO, Singh AS, Hsieh T, Nathanson D, Herschman HR, Phelps ME, Witte ON, Czernin J, Radu CG. Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. J Exp Med. 2012 Nov 19; 209(12):2215-28. PMID: 23148236.
      View in: PubMed
    95. Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clin. 2013 Apr; 8(2):201-17. PMID: 27157948.
      View in: PubMed
    96. Karantanis D, Kalkanis D, Allen-Auerbach M, Bogsrud TV, Subramaniam RM, Danielson A, Lowe VJ, Czernin J. Oncologic 18F-FDG PET/CT: referring physicians' point of view. J Nucl Med. 2012 Oct; 53(10):1499-505. PMID: 22917886.
      View in: PubMed
    97. Lee P, Kupelian P, Czernin J, Ghosh P. Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer. Front Oncol. 2012; 2:71. PMID: 22798989.
      View in: PubMed
    98. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol. 2012 Aug; 14(8):1079-89. PMID: 22711609.
      View in: PubMed
    99. Karantanis D, Allen-Auerbach M, Czernin J. Squamous papilloma of the oral cavity and oropharynx on 18F-FDG PET/CT imaging. Clin Nucl Med. 2012 May; 37(5):e98-9. PMID: 22475925.
      View in: PubMed
    100. Yaghoubi SS, Campbell DO, Radu CG, Czernin J. Positron emission tomography reporter genes and reporter probes: gene and cell therapy applications. Theranostics. 2012; 2(4):374-91. PMID: 22509201.
      View in: PubMed
    101. Herschman HR, Czernin J. A spotlight from prostate cancer. Cancer Discov. 2012 Apr; 2(4):301-3. PMID: 22576205.
      View in: PubMed
    102. Walter F, Czernin J, Hall T, Allen-Auerbach M, Walter MA, Dunkelmann S, Federman N. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients? J Pediatr Hematol Oncol. 2012 Mar; 34(2):131-6. PMID: 22134608.
      View in: PubMed
    103. Herrmann K, Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Schuster T, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res. 2012 Apr 01; 18(7):2024-31. PMID: 22338012.
      View in: PubMed
    104. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. J Nucl Med. 2012 Mar; 53(3):393-8. PMID: 22323780.
      View in: PubMed
    105. Lee JT, Campbell DO, Satyamurthy N, Czernin J, Radu CG. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-ß-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-ß-L-arabinofuranosyl)-5-methylcytosine PET. J Nucl Med. 2012 Feb; 53(2):275-80. PMID: 22302964.
      View in: PubMed
    106. Karantanis D, Allen-Auerbach M, Czernin J. Sources and resources for oncologists to help answer the question: is PET/CT appropriate for my patient? Hell J Nucl Med. 2012 Jan-Apr; 15(1):2-8. PMID: 22413105.
      View in: PubMed
    107. Karantanis D, Allen-Auerbach M, Czernin J. Relationship among glycolytic phenotype, grade, and histological subtype in ovarian carcinoma. Clin Nucl Med. 2012 Jan; 37(1):49-53. PMID: 22157028.
      View in: PubMed
    108. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012 Jan; 53(1):29-36. PMID: 22159180.
      View in: PubMed
    109. Czernin J, Weber WA. Issues and controversies in nuclear medicine. Introduction. J Nucl Med. 2011 Dec; 52 Suppl 2:1S-2S. PMID: 22144550.
      View in: PubMed
    110. Yang Y, Czernin J. Contribution of imaging to cancer care costs. J Nucl Med. 2011 Dec; 52 Suppl 2:86S-92S. PMID: 22144560.
      View in: PubMed
    111. Campbell DO, Yaghoubi SS, Su Y, Lee JT, Auerbach MS, Herschman H, Satyamurthy N, Czernin J, Lavie A, Radu CG. Structure-guided engineering of human thymidine kinase 2 as a positron emission tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. J Biol Chem. 2012 Jan 02; 287(1):446-54. PMID: 22074768.
      View in: PubMed
    112. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS. (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med. 2011 Nov; 52(11):1684-1689. PMID: 22045706.
      View in: PubMed
    113. Benz MR, Czernin J, Allen-Auerbach MS, Dry SM, Sutthiruangwong P, Spick C, Radu C, Weber WA, Tap WD, Eilber FC. 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma: a pilot study to correlate imaging findings with tissue thymidine kinase 1 and Ki-67 activity and histopathologic response. Cancer. 2012 Jun 15; 118(12):3135-44. PMID: 22020872.
      View in: PubMed
    114. Walter F, Federman N, Apichairuk W, Nelson S, Phelps ME, Allen-Auerbach M, Walter MA, Czernin J. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients. Pediatr Hematol Oncol. 2011 Oct; 28(7):579-87. PMID: 21936620.
      View in: PubMed
    115. Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. Discriminant analysis of ¹8F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011 Oct 15; 17(20):6553-62. PMID: 21868765.
      View in: PubMed
    116. Maddahi J, Czernin J, Lazewatsky J, Huang SC, Dahlbom M, Schelbert H, Sparks R, Ehlgen A, Crane P, Zhu Q, Devine M, Phelps M. Phase I, first-in-human study of BMS747158, a novel 18F-labeled tracer for myocardial perfusion PET: dosimetry, biodistribution, safety, and imaging characteristics after a single injection at rest. J Nucl Med. 2011 Sep; 52(9):1490-8. PMID: 21849402.
      View in: PubMed
    117. Beyer T, Freudenberg LS, Czernin J, Townsend DW. The future of hybrid imaging-part 3: PET/MR, small-animal imaging and beyond. Insights Imaging. 2011 Jun; 2(3):235-246. PMID: 22347950.
      View in: PubMed
    118. Beyer T, Townsend DW, Czernin J, Freudenberg LS. The future of hybrid imaging-part 2: PET/CT. Insights Imaging. 2011 Jun; 2(3):225-34. PMID: 23099865.
      View in: PubMed
    119. Macapinlac HA, Czernin J, Larson SM. Practice based evidence of the beneficial impact of PET in patients with brain tumors. Mol Imaging Biol. 2011 Feb; 13(1):1-2. PMID: 21082268.
      View in: PubMed
    120. Beyer T, Freudenberg LS, Townsend DW, Czernin J. The future of hybrid imaging-part 1: hybrid imaging technologies and SPECT/CT. Insights Imaging. 2011 Apr; 2(2):161-9. PMID: 23099842.
      View in: PubMed
    121. Ng QK, Su H, Armijo AL, Czernin J, Radu CG, Segura T. Clustered Arg-Gly-Asp peptides enhances tumor targeting of nonviral vectors. ChemMedChem. 2011 Apr 04; 6(4):623-7. PMID: 21442757.
      View in: PubMed
    122. Walter MA, Benz MR, Hildebrandt IJ, Laing RE, Hartung V, Damoiseaux RD, Bockisch A, Phelps ME, Czernin J, Weber WA. Metabolic imaging allows early prediction of response to vandetanib. J Nucl Med. 2011 Feb; 52(2):231-40. PMID: 21233183.
      View in: PubMed
    123. Beyer T, Czernin J, Freudenberg LS. Variations in clinical PET/CT operations: results of an international survey of active PET/CT users. J Nucl Med. 2011 Feb; 52(2):303-10. PMID: 21233186.
      View in: PubMed
    124. Czernin J, Benz MR, Allen-Auerbach MS. Breast cancer. Methods Mol Biol. 2011; 727:141-70. PMID: 21331933.
      View in: PubMed
    125. Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur J Nucl Med Mol Imaging. 2011 Apr; 38(4):711-21. PMID: 21127859.
      View in: PubMed
    126. Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med. 2010 Dec; 51(12):1826-9. PMID: 21078790.
      View in: PubMed
    127. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010 Oct; 51(10):1532-8. PMID: 20847166.
      View in: PubMed
    128. Walter MA, Hildebrandt IJ, Hacke K, Kesner AL, Kelly O, Lawson GW, Phelps ME, Czernin J, Weber WA, Schiestl RH. Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice. J Nucl Med. 2010 Aug; 51(8):1285-92. PMID: 20660381.
      View in: PubMed
    129. Benz MR, Dry SM, Eilber FC, Allen-Auerbach MS, Tap WD, Elashoff D, Phelps ME, Czernin J. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med. 2010 Aug; 51(8):1174-81. PMID: 20660389.
      View in: PubMed
    130. Shu CJ, Campbell DO, Lee JT, Tran AQ, Wengrod JC, Witte ON, Phelps ME, Satyamurthy N, Czernin J, Radu CG. Novel PET probes specific for deoxycytidine kinase. J Nucl Med. 2010 Jul; 51(7):1092-8. PMID: 20554721.
      View in: PubMed
    131. Benz MR, Czernin J, Tap WD, Eckardt JJ, Seeger LL, Allen-Auerbach MS, Dry SM, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. Sarcoma. 2010; 2010:143540. PMID: 20414348.
      View in: PubMed
    132. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010 May; 51(5):720-7. PMID: 20395318.
      View in: PubMed
    133. Ribas A, Benz MR, Allen-Auerbach MS, Radu C, Chmielowski B, Seja E, Williams JL, Gomez-Navarro J, McCarthy T, Czernin J. Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab. J Nucl Med. 2010 Mar; 51(3):340-6. PMID: 20150263.
      View in: PubMed
    134. Czernin J, Benz MR, Allen-Auerbach MS. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol. 2010 Mar; 73(3):470-80. PMID: 20097498.
      View in: PubMed
    135. Benz MR, Czernin J, Dry SM, Tap WD, Allen-Auerbach MS, Elashoff D, Phelps ME, Weber WA, Eilber FC. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer. 2010 Jan 15; 116(2):451-8. PMID: 19924789.
      View in: PubMed
    136. Toy G, Austin WR, Liao HI, Cheng D, Singh A, Campbell DO, Ishikawa TO, Lehmann LW, Satyamurthy N, Phelps ME, Herschman HR, Czernin J, Witte ON, Radu CG. Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A. 2010 Mar 23; 107(12):5551-6. PMID: 20080663.
      View in: PubMed
    137. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):12932-7. PMID: 19625624.
      View in: PubMed
    138. Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009 Jul; 21(4):345-51. PMID: 19412096.
      View in: PubMed
    139. Schluep T, Hwang J, Hildebrandt IJ, Czernin J, Choi CH, Alabi CA, Mack BC, Davis ME. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A. 2009 Jul 07; 106(27):11394-9. PMID: 19564622.
      View in: PubMed
    140. Johnson M, Karanikolas BD, Priceman SJ, Powell R, Black ME, Wu HM, Czernin J, Huang SC, Wu L. Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor. J Nucl Med. 2009 May; 50(5):757-64. PMID: 19372484.
      View in: PubMed
    141. Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC. FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15; 15(8):2856-63. PMID: 19351756.
      View in: PubMed
    142. Czernin J, Benz MR, Allen-Auerbach MS. PET Imaging of Prostate Cancer Using C-Acetate. PET Clin. 2009 Apr; 4(2):163-72. PMID: 21984877.
      View in: PubMed
    143. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS. Comparison of CT, PET, and PET/CT for staging of patients with indolent non-Hodgkin's lymphoma. Mol Imaging Biol. 2009 Jul-Aug; 11(4):269-74. PMID: 19326177.
      View in: PubMed
    144. Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res. 2009 Apr 01; 69(7):3173-9. PMID: 19318569.
      View in: PubMed
    145. Imani F, Agopian VG, Auerbach MS, Walter MA, Imani F, Benz MR, Dumont RA, Lai CK, Czernin JG, Yeh MW. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009 Apr; 50(4):513-9. PMID: 19289420.
      View in: PubMed
    146. Laing RE, Walter MA, Campbell DO, Herschman HR, Satyamurthy N, Phelps ME, Czernin J, Witte ON, Radu CG. Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A. 2009 Feb 24; 106(8):2847-52. PMID: 19196993.
      View in: PubMed
    147. Wang H, Wang S, Su H, Chen KJ, Armijo AL, Lin WY, Wang Y, Sun J, Kamei K, Czernin J, Radu CG, Tseng HR. A supramolecular approach for preparation of size-controlled nanoparticles. Angew Chem Int Ed Engl. 2009; 48(24):4344-8. PMID: 19425037.
      View in: PubMed
    148. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, Gambhir SS. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 2009 Jan; 6(1):53-8. PMID: 19015650.
      View in: PubMed
    149. Wei LH, Olafsen T, Radu C, Hildebrandt IJ, McCoy MR, Phelps ME, Meares C, Wu AM, Czernin J, Weber WA. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. J Nucl Med. 2008 Nov; 49(11):1828-35. PMID: 18927335.
      View in: PubMed
    150. Benz MR, Allen-Auerbach MS, Eilber FC, Chen HJ, Dry S, Phelps ME, Czernin J, Weber WA. Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas. J Nucl Med. 2008 Oct; 49(10):1579-84. PMID: 18794268.
      View in: PubMed
    151. Kesner AL, Hsueh WA, Czernin J, Padgett H, Phelps ME, Silverman DH. Radiation dose estimates for [18F]5-fluorouracil derived from PET-based and tissue-based methods in rats. Mol Imaging Biol. 2008 Nov-Dec; 10(6):341-8. PMID: 18679756.
      View in: PubMed
    152. Kesner AL, Lau VK, Speiser M, Hsueh WA, Agazaryan N, DeMarco JJ, Czernin J, Silverman DH. Time-course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow. J Appl Clin Med Phys. 2008 Jun 23; 9(3):2747. PMID: 18716585.
      View in: PubMed
    153. Benz MR, Evilevitch V, Allen-Auerbach MS, Eilber FC, Phelps ME, Czernin J, Weber WA. Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008 Jul; 49(7):1038-46. PMID: 18552153.
      View in: PubMed
    154. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res. 2008 Jun 01; 14(11):3416-26. PMID: 18519772.
      View in: PubMed
    155. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009 Aug; 71(2):242-8. PMID: 18511228.
      View in: PubMed
    156. Weber WA, Grosu AL, Czernin J. Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning. Nat Clin Pract Oncol. 2008 Mar; 5(3):160-70. PMID: 18253106.
      View in: PubMed
    157. Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am. 2008 Mar; 46(2):199-211, vii. PMID: 18619376.
      View in: PubMed
    158. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008 Jun; 35(6):1089-99. PMID: 18239919.
      View in: PubMed
    159. Evilevitch V, Weber WA, Tap WD, Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ, Elashoff RM, Phelps ME, Czernin J, Eilber FC. Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2008 Feb 01; 14(3):715-20. PMID: 18245531.
      View in: PubMed
    160. Weber WA, Czernin J, Phelps ME, Herschman HR. Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol. 2008 Jan; 5(1):44-54. PMID: 18097456.
      View in: PubMed
    161. Kesner AL, Hsueh WA, Htet NL, Pio BS, Czernin J, Pegram MD, Phelps ME, Silverman DH. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med. 2007 Dec; 48(12):2021-7. PMID: 18006620.
      View in: PubMed
    162. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007 Oct 20; 25(30):4714-21. PMID: 17947718.
      View in: PubMed
    163. Weber WA, Czernin J, Phelps ME. Prognostic significance of fluorodeoxyglucose uptake in non-small cell lung cancer. A blurry picture? Clin Cancer Res. 2007 Jun 01; 13(11):3105-6. PMID: 17545510.
      View in: PubMed
    164. Lin TW, de Aburto MA, Dahlbom M, Huang LL, Marvi MM, Tang M, Czernin J, Phelps ME, Silverman DH. Predicting seizure-free status for temporal lobe epilepsy patients undergoing surgery: prognostic value of quantifying maximal metabolic asymmetry extending over a specified proportion of the temporal lobe. J Nucl Med. 2007 May; 48(5):776-82. PMID: 17475967.
      View in: PubMed
    165. Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C. Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med. 2007 Feb; 48(2):214-20. PMID: 17268017.
      View in: PubMed
    166. Halpern BS, Yeom K, Fueger BJ, Lufkin RB, Czernin J, Allen-Auerbach M. Evaluation of suspected local recurrence in head and neck cancer: a comparison between PET and PET/CT for biopsy proven lesions. Eur J Radiol. 2007 May; 62(2):199-204. PMID: 17223003.
      View in: PubMed
    167. Czernin J, Schelbert HR. PET/CT in cancer patient management. Introduction. J Nucl Med. 2007 Jan; 48 Suppl 1:2S-3S. PMID: 17204715.
      View in: PubMed
    168. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007 Jan; 48 Suppl 1:78S-88S. PMID: 17204723.
      View in: PubMed
    169. Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, Phelps ME, Silverman DH. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med. 2006 Dec; 47(12):1995-9. PMID: 17138742.
      View in: PubMed
    170. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006 Oct 01; 12(19):5659-67. PMID: 17020967.
      View in: PubMed
    171. Kesner AL, Dahlbom M, Huang SC, Hsueh WA, Pio BS, Czernin J, Kreissl M, Wu HM, Silverman DH. Semiautomated analysis of small-animal PET data. J Nucl Med. 2006 Jul; 47(7):1181-6. PMID: 16818953.
      View in: PubMed
    172. Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, Phelps ME, Weber WA. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006 Jun; 47(6):999-1006. PMID: 16741310.
      View in: PubMed
    173. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006 Jun; 47(6):904-11. PMID: 16741298.
      View in: PubMed
    174. Allen-Auerbach M, Yeom K, Park J, Phelps M, Czernin J. Standard PET/CT of the chest during shallow breathing is inadequate for comprehensive staging of lung cancer. J Nucl Med. 2006 Feb; 47(2):298-301. PMID: 16455636.
      View in: PubMed
    175. Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, Weber WA. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006 Feb; 129(2):393-401. PMID: 16478857.
      View in: PubMed
    176. Pio BS, Park CK, Pietras R, Hsueh WA, Satyamurthy N, Pegram MD, Czernin J, Phelps ME, Silverman DH. Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006 Jan-Feb; 8(1):36-42. PMID: 16362149.
      View in: PubMed
    177. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med. 2006; 57:99-118. PMID: 16409139.
      View in: PubMed
    178. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, Fueger B, Czernin J, Sawyers CL. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006 Jan; 12(1):122-7. PMID: 16341243.
      View in: PubMed
    179. Gangloff A, Hsueh WA, Kesner AL, Kiesewetter DO, Pio BS, Pegram MD, Beryt M, Townsend A, Czernin J, Phelps ME, Silverman DH. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med. 2005 Nov; 46(11):1866-71. PMID: 16269601.
      View in: PubMed
    180. Halpern BS, Schiepers C, Weber WA, Crawford TL, Fueger BJ, Phelps ME, Czernin J. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest. 2005 Oct; 128(4):2289-97. PMID: 16236886.
      View in: PubMed
    181. Fueger BJ, Weber WA, Quon A, Crawford TL, Allen-Auerbach MS, Halpern BS, Ratib O, Phelps ME, Czernin J. Performance of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography and integrated PET/CT in restaged breast cancer patients. Mol Imaging Biol. 2005 Sep-Oct; 7(5):369-76. PMID: 16220355.
      View in: PubMed
    182. Tran A, Pio BS, Khatibi B, Czernin J, Phelps ME, Silverman DH. 18F-FDG PET for staging breast cancer in patients with inner-quadrant versus outer-quadrant tumors: comparison with long-term clinical outcome. J Nucl Med. 2005 Sep; 46(9):1455-9. PMID: 16157527.
      View in: PubMed
    183. Brunken RC, Perloff JK, Czernin J, Campisi R, Purcell S, Miner PD, Child JS, Schelbert HR. Myocardial perfusion reserve in adults with cyanotic congenital heart disease. Am J Physiol Heart Circ Physiol. 2005 Nov; 289(5):H1798-806. PMID: 16006539.
      View in: PubMed
    184. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005 Jun; 46(6):945-52. PMID: 15937304.
      View in: PubMed
    185. Kim JH, Czernin J, Allen-Auerbach MS, Halpern BS, Fueger BJ, Hecht JR, Ratib O, Phelps ME, Weber WA. Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005 Apr; 46(4):587-95. PMID: 15809480.
      View in: PubMed
    186. Halpern BS, Dahlbom M, Auerbach MA, Schiepers C, Fueger BJ, Weber WA, Silverman DH, Ratib O, Czernin J. Optimizing imaging protocols for overweight and obese patients: a lutetium orthosilicate PET/CT study. J Nucl Med. 2005 Apr; 46(4):603-7. PMID: 15809482.
      View in: PubMed
    187. Czernin J, Auerbach MA. Clinical PET/CT imaging: promises and misconceptions. Nuklearmedizin. 2005; 44 Suppl 1:S18-23. PMID: 16395974.
      View in: PubMed
    188. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, Weber WA, Stout D, Satyamurthy N, Barrio J, Phelps ME, Silverman DH, Sawyers CL, Czernin J. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med. 2005 Jan; 46(1):114-20. PMID: 15632041.
      View in: PubMed
    189. Allen-Auerbach M, Quon A, Weber WA, Obrzut S, Crawford T, Silverman DH, Ratib O, Phelps ME, Czernin J. Comparison between 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol. 2004 Nov-Dec; 6(6):411-6. PMID: 15564152.
      View in: PubMed
    190. Czernin J, Weber W. Translational molecular imaging. Mol Imaging Biol. 2004 Jul-Aug; 6(4):181-2. PMID: 15262232.
      View in: PubMed
    191. Halpern BS, Dahlbom M, Quon A, Schiepers C, Waldherr C, Silverman DH, Ratib O, Czernin J. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med. 2004 May; 45(5):797-801. PMID: 15136629.
      View in: PubMed
    192. Obrzut SL, Halpern BS, Monchamp T, Grabski K, Watts WJ, Czernin J. The role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography in monitoring the immunosuppressive therapy response of inflammatory myofibroblastic tumor. Mol Imaging Biol. 2004 May-Jun; 6(3):126-30. PMID: 15193246.
      View in: PubMed
    193. Halpern BS, Dahlbom M, Waldherr C, Yap CS, Schiepers C, Silverman DH, Ratib O, Czernin J. Cardiac pacemakers and central venous lines can induce focal artifacts on CT-corrected PET images. J Nucl Med. 2004 Feb; 45(2):290-3. PMID: 14960650.
      View in: PubMed
    194. Filmont JE, Yap CS, Ko F, Vranjesevic D, Quon A, Margolis DJ, Safaei A, Emmanouilides C, Silverman DH, Phelps ME, Czernin J. Conventional imaging and 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of patients with previously treated Hodgkin's disease. Mol Imaging Biol. 2004 Jan-Feb; 6(1):47-54. PMID: 15018828.
      View in: PubMed
    195. Silverman DH, Truong CT, Kim SK, Chang CY, Chen W, Kowell AP, Cummings JL, Czernin J, Small GW, Phelps ME. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Mol Genet Metab. 2003 Nov; 80(3):350-5. PMID: 14680983.
      View in: PubMed
    196. Vranjesevic D, Schiepers C, Silverman DH, Quon A, Villalpando J, Dahlbom M, Phelps ME, Czernin J. Relationship between 18F-FDG uptake and breast density in women with normal breast tissue. J Nucl Med. 2003 Aug; 44(8):1238-42. PMID: 12902413.
      View in: PubMed
    197. Filmont JE, Czernin J, Yap C, Silverman DH, Quon A, Phelps ME, Emmanouilides C. Value of F-18 fluorodeoxyglucose positron emission tomography for predicting the clinical outcome of patients with aggressive lymphoma prior to and after autologous stem-cell transplantation. Chest. 2003 Aug; 124(2):608-13. PMID: 12907550.
      View in: PubMed
    198. Filmont JE, Vranjesevic D, Quon A, Margolis DJ, Ko F, Safaei A, Emmanouilides C, Silverman DH, Rao J, Valk PE, Phelps ME, Czernin J. Conventional imaging and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography for predicting the clinical outcome of previously treated non-Hodgkin's lymphoma patients. Mol Imaging Biol. 2003 Jul-Aug; 5(4):232-9. PMID: 14499138.
      View in: PubMed
    199. Pio BS, Byrne FR, Aranda R, Boulay G, Spicher K, Song MH, Birnbaumer L, Phelps ME, Czernin J, Silverman DH. Noninvasive quantification of bowel inflammation through positron emission tomography imaging of 2-deoxy-2-[18F]fluoro-D-glucose-labeled white blood cells. Mol Imaging Biol. 2003 Jul-Aug; 5(4):271-7. PMID: 14499142.
      View in: PubMed
    200. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2003 Jun; 30 Suppl 1:S82-8. PMID: 12719922.
      View in: PubMed
    201. Czernin J, Waldherr C. Cigarette smoking and coronary blood flow. Prog Cardiovasc Dis. 2003 Mar-Apr; 45(5):395-404. PMID: 12704596.
      View in: PubMed
    202. Schöder H, Brown K, Said J, Czernin J. A patient with primary cardiac lymphoma. Mol Imaging Biol. 2002 Jul; 4(4):274-5. PMID: 14537116.
      View in: PubMed
    203. Silverman DH, Cummings JL, Small GW, Gambhir SS, Chen W, Czernin J, Phelps ME. Added clinical benefit of incorporating 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol. 2002 Jul; 4(4):283-93. PMID: 14537119.
      View in: PubMed
    204. Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging. 2002 Sep; 29(9):1166-73. PMID: 12192561.
      View in: PubMed
    205. Seltzer MA, Yap CS, Silverman DH, Meta J, Schiepers C, Phelps ME, Gambhir SS, Rao J, Valk PE, Czernin J. The impact of PET on the management of lung cancer: the referring physician's perspective. J Nucl Med. 2002 Jun; 43(6):752-6. PMID: 12050318.
      View in: PubMed
    206. Wong C, Silverman DH, Seltzer M, Schiepers C, Ariannejad M, Gambhir SS, Phelps ME, Rao J, Valk P, Czernin J. The impact of 2-deoxy-2[18F] fluoro-D-glucose whole body positron emission tomography for managing patients with melanoma: the referring physician's perspective. Mol Imaging Biol. 2002 Mar; 4(2):185-90. PMID: 14537142.
      View in: PubMed
    207. Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002 Mar; 43(3):325-9. PMID: 11884491.
      View in: PubMed
    208. Silverman DH, Gambhir SS, Huang HW, Schwimmer J, Kim S, Small GW, Chodosh J, Czernin J, Phelps ME. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med. 2002 Feb; 43(2):253-66. PMID: 11850493.
      View in: PubMed
    209. Czernin J. Clinical applications of FDG-PET in oncology. Acta Med Austriaca. 2002; 29(5):162-70. PMID: 12506767.
      View in: PubMed
    210. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med. 2002; 53:89-112. PMID: 11818465.
      View in: PubMed
    211. Czernin J. FDG-PET in breast cancer: a different view of its clinical usefulness. Mol Imaging Biol. 2002 Jan; 4(1):35-45. PMID: 14538047.
      View in: PubMed